Founded in 2011, Haemokinesis® is transforming blood grouping.
Headquartered in Melbourne, Australia, with a production and distribution facility in Switzerland, Haemokinesis® is led by a team of leading Australian clinical diagnostics experts. Together they have spent the last decade creating innovative solutions in blood grouping and emergency medicine.
Haemokinesis® researches, develops and manufactures products which provide results to medical professionals in clinically relevant timeframes.
Our innovative semi-automated and automated analysers streamline testing and analysis. Each has been created closely with healthcare professionals to close the gaps present in laboratories, hospitals and wherever testing is needed.
Haemokinesis® has a growing global presence across the world via direct sales and distributor networks, including Africa, Asia-Pacific, Europe, Middle East and North and South America.
At Haemokinesis®, we deliver advanced blood diagnostic and testing technology that’s safe, fast, accurate and reliable.
We are solving the challenges of point-of-trauma blood diagnostics and the limitations of existing blood testing in hospitals and blood banks. We speed up and simplify diagnostic testing and analysis for medical professionals to improve patient outcomes and help save lives.
Haemokinesis® is committed to removing the barriers of access to the basic elements of healthcare around the world. Focused on blood group testing and emergency medicine. Haemokinesis® provides safe and timely blood group testing as a fundamental requirement of a healthcare system and innovative point-of-care solutions in emergency medicine, the Company’s vision is to ensure anyone, anywhere has access to vital diagnostic technology.
Haemokinesis journey begins!
Haemokinesis® established on 27th Sept 2011.
Development of STARGEL10 & STATUS1
STARGEL10® & STATUS1® was successfully created and the World’s fastest Gel test was born in 2012.
ISO 9001:2008 Certification
Setting up a new company from the ground up was no easy task and the team at Haemokinesis® were successful at receiving ISO 9001:2008 accreditation in 2013.
ISO 13485 accreditation
Haemokinesis® staff achieved the ISO 13485 medical device certification in 2018.
Swiss facility acquired
2018 saw the acquisition of a purpose built facility in Switzerland.
DAYmate S machine Launch
2018 also saw the launch of the Haemokinesis® updated DAYmate S machine.
CE Mark for STARGEL10® & STATUS1®
June 2018 Haemokinesis® receives CE mark certification for its STARGEL10® and STATUS1® instruments and consumables.
STARGEL10 & STATUS1 approved by TGA
TGA approves Haemokinesis’ STARGEL10® and STATUS1® products in 2019 for the Australian market.
Eclipse automate launched
January 2020 sees the launch of the Haemokinesis® high throughput analyser, Haemokinesis Eclipse®, for STARGEL10® applications. Redefining expectations of a large laboratory analyser, in terms of speed, capacity, throughput, STAT management and productivity.
Our team at Haemokinesis® bring extensive expertise and experience in healthcare, pharmaceuticals using their talents to grow and innovate the blood diagnostic sector.
Chief Executive Officer
Michael Bernard Ohanessian brings extensive experience gained from technology-related businesses with a mixture of operational, strategic and leadership capabilities. Following a ten-year career at Mobil Oil, Michael joined the Boston Consulting Group where he consulted to clients in a wide range of industries which include banking, airlines, mining, packaging, sports, oil and gas, retailing and biotechnology.
Michael became the CEO of Vision BioSystems (now Leica BioSystems) where he led a transformation over seven years into a globally successful medical diagnostics company. He has also served as CEO and Managing Director of ASX-listed Genetic Technologies Limited and has been involved in investment management and corporate advice with Lion Capital. Michael then joined ASX-listed Praemium Limited as its CEO and Managing Director from 2011 to 2021. Michael was a Non-Executive Director of the SGP Group of Companies (now Trajan) and has been a Non-Executive Director of ASX-listed Bluechiip since 2014.
Instrument & Software Operating Officer
Raoul has been involved with Haemokinesis since 2014, where he was in charge of software development before joining the company in 2018, when he became COO and implemented software and instrument production improvements. Raoul’s extensive experience, including IT knowledge, saw him work as a consultant for some of the most important companies in Italy and abroad: the Italian Automobile Club (ACI), Publitalia’80 (Mediaset Group) and other top International Motorsport Federations.
In more than 25 years, Raoul learned to master many different technologies, particularly focused on the development of complex and functional product management architectures. His passion for streamlining industry and processes brought him to become a certified Six Sigma Black Belt, with also a certification in Scrum Agile project management.
Siobhan Mc Andrew
Regulatory and Quality Manager
Siobhan joined Haemokinesis in 2012 as Production Manager soon after Haemokinesis was established. Siobhan has over 16 years’ experience in the Immunohaemolatology Industry starting her career with Dia-Med Australia before moving on to Lateral Grifols. She moved from Ireland to Australia in 2004 after completing a 4 years honours degree in Bachelor of Science, majoring in Industrial Microbiology from University College Dublin (UCD).
During her career she has worked on research, design, production and regulatory adherence of diagnostic reagents. Siobhan has brought her knowledge and skill into the Haemokinesis portfolio and is committed to compliant and high-quality products.
Dr Sanjeev Alfred
PhD, MBA, MAICD
Chief Commercial Officer
Sanjeev joined Haemokinesis in April 2021. Sanjeev has substantial experience in the immunohaematology and clinical diagnostics sector joining us, from Bio-Rad Laboratories (BIO:NYSE). Sanjeev was previously the Regional Manager (South Pacific Region), Clinical Diagnostics Group at Bio-Rad and prior to that was the Regional Marketing Manager (Asia-Pacific) at Thermo Fisher Scientific (TMO:NYSE).
Sanjeev has more than 15 years of experience in the Life Science and Clinical diagnostic markets. Furthermore, he has significant experience in establishing distributors and large-scale distributor networks. Sanjeev holds a PhD (Biological Sciences) from the University of Sydney along with an Executive MBA from the Australian Catholic University. He is also a member of the Australian Institute of Company directors.
Dr Natasha Yeow
Natasha joined Haemokinesis in 2017 as Production Validation Specialist after completing her PhD (Chemical Engineering) as part of a collaboration between Monash University and Haemokinesis. Prior to that, she has had 3 years of Immunohaematology experience working as a Production Scientist in the Production and QC department of Grifols Australia. In her 6 years with Haemokinesis, she has been involved in product research and development, product validation and registration, and the management of the QC team.